How Does bluebird bio Inc (BLUE) Stock Rank on Wall Street Tuesday?
At least five startups have emerged with new ways to genetically modify immune cells within the body, an approach that, if successful, could widen the field of CAR-T treatment.
Read these LinkedIn profile tips from an expert talent consultant. Make your profile more effective in finding a biotech or biopharma job
The Regenerative Medicine Market analysis offers historical and current scenario of the global market offering competency based analysis and global market estimates The Regenerative Medicine analysis provides a comprehensive investigation into the geographical landscape and industry size along with…
bluebird bio Inc (BLUE) is up 1.60% Wednesday In Premarket Trading
At the Cell & Gene Meeting on the Mesa, gene therapy leaders discussed the challenges of bringing these transformative medicines to market.
CBER maps modernization plan to handle surge in research and applications.
“Global Cancer Gene Therapy Market” the new research report adds to Data Bridge Market Research’s reports database. This Research Report is spread across 350
Recent Phase I trial data spurred BMS to launch a larger study of MCARH109 and inspired investigators to explore the efficacy of targeting GPR5CD and BCMA with CAR T-cell therapies.
Increasing lifestyle changes, including increasing consumption of tobacco and alcohol, which leads to increased risk of cancer, trigger growth in the...
Gene therapy market growth is fueled by high investment for R&D activities related to gene therapy and increasing awareness of gene therapy, in
Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.
The week in pharma: action, reaction and insight – week to September 30
AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know
If all things go according to plan, the FDA could start reviewing the first-ever filing for a CRISPR therapy this November. Vertex and CRISPR Therapeutics say they have wrapped up their lengthy talks with the agency and gotten regulators on board for a rolling review beginning later this year —
“The Market Research Intellect has added a new statistical market report to its repositor
With four days left in the fiscal year, FDA-related policy riders approved in both House and Senate committees, at least for now, appear dead, according to the text of a short-term government spending bill unveiled late last night to keep federal agencies open until Dec. 16. But the absence of
While U.S. FDA approvals are down by 27% in 2022, the agency was busy throughout the month of September, clearing seven new molecular entities (NMEs), the most for any month this year.
The Genome Engineering Market Industry research forecast to 2022–2028 offers in-depth market information to help companies develop growth strategies and
With US stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: